Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Revenio Group OyjREVXF 80 Debt-to-EBITDA is 0.35 as of Mar. 2026, which is 31% below its 10-year median of 0.51. GuruFocus rates REVXF with a GF Score™ of 80/100 and a GF Value™ of $38.37. The stock has 2 warning signs investors should review. Among 472 Medical Devices & Instruments companies, Revenio Group Oyj ranks better than 84.11% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Revenio Group Oyj's Debt-to-EBITDA or its related term are showing as below:
REVXF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.03 Med: 0.51 Max: 1.99
Current: 0.19
During the past 13 years, the highest Debt-to-EBITDA Ratio of Revenio Group Oyj was 1.99. The lowest was 0.03. And the median was 0.51.
REVXF's Debt-to-EBITDA is ranked better than 84.11% of 472
companies
in the Medical Devices & Instruments industry
Industry Median: 1.64
vs REVXF: 0.19
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Revenio Group Oyj Debt-to-EBITDA Related Terms
Revenio Group Oyj Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Revenio Group Oyj's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Revenio Group Oyj's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revenio Group Oyj Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Revenio Group Oyj's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Revenio Group Oyj's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Revenio Group Oyj (REVXF) has a Debt-to-EBITDA of 0.35 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Revenio Group Oyj. This is 31% below median its historical median of 0.51. Over the past decade, Revenio Group Oyj's Debt-to-EBITDA has ranged from 0.03 to 1.99. According to the industry distribution chart, Revenio Group Oyj ranks #75 out of 472 companies in the Medical Devices & Instruments industry, placing it in the top 15.9%.
Is Revenio Group Oyj's Debt-to-EBITDA too high?
Revenio Group Oyj's current Debt-to-EBITDA of 0.35 is 31% below median its 10-year median of 0.51. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 1.99. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.64. Revenio Group Oyj's value of 0.35 is 78.7% below this industry median. Based on the distribution chart, Revenio Group Oyj ranks #75 out of 472 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Revenio Group Oyj has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Revenio Group Oyj's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Revenio Group Oyj ranks #75 out of 472 companies for Debt-to-EBITDA. This places Revenio Group Oyj in the top 16% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.64. Revenio Group Oyj's value of 0.35 is 78.7% below this benchmark. Historically, Revenio Group Oyj's own Debt-to-EBITDA has ranged from 0.03 to 1.99 over the past decade. While the company's 10-year median is 0.51 vs. the industry median of 1.64, Revenio Group Oyj has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.64, based on 472 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Revenio Group Oyj's current Debt-to-EBITDA of 0.35 is 78.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Revenio Group Oyj. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Revenio Group Oyj's current Debt-to-EBITDA is 0.35, which is 31% below median its own 10-year median of 0.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revenio Group Oyj stock overvalued right now?
Revenio Group Oyj (REVXF) has a current Debt-to-EBITDA of 0.35. The stock's GF Value™ is $38.37, compared to a current price of $16.41 — trading 57.2% below its estimated fair value. The current Debt-to-EBITDA is 0.35, which is 31% below median its 10-year median of 0.51 and 78.7% below the Medical Devices & Instruments industry median of 1.64. Revenio Group Oyj's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Revenio Group Oyj (REVXF), the current Debt-to-EBITDA is 0.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Revenio Group Oyj (REVXF) Overvalued in 2026?
Based on GuruFocus' analysis, Revenio Group Oyj stock appears to be undervalued.
The current stock price of $16.41 is trading 57.2% below its estimated GF Value™ of $38.37.
Key valuation signals for REVXF:
Debt-to-EBITDA: 0.35 (31% below median its 10-year median of 0.51)
GF Value™: $38.37 vs. price of $16.41 (57.2% below fair value)
Industry Position: 78.7% below the Medical Devices & Instruments median (#75 of 472)
No single metric tells the full story. See the REVXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Revenio Group Oyj is a Finnish health technology company. It develops and commercializes effective, easy-to-use health tech-related screening devices for detecting diseases of public health significance. Its ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), and perimeter and fundus imaging devices under the iCare brand. Its eye care software platform, Oculo, offers clinical communication, telehealth, remote patient monitoring, and data analytics capabilities. The company generates the majority of its revenue from the United States.
80GF Score
Get the complete analysis for REVXF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
REVXF has been successfully added to your 
